Royalty Pharma (RPRX) Net Income towards Common Stockholders (QoQ) (2019 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Net Income towards Common Stockholders (QoQ) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Orix | 44.91 Bn | 45.24 Bn | 4.68 Bn |
| 2 | Royalty Pharma | 36.78 Bn | 38.89 Bn | - |
| 3 | Royal Gold | 22.19 Bn | 22.06 Bn | 390.45 Mn |
| 4 | OR Royalties | 6.98 Bn | 6.91 Bn | 82.22 Mn |
| 5 | Encore Capital | 2.06 Bn | 1.88 Bn | 455.04 Mn |
| 6 | Atlanticus Holdings | 1.41 Bn | 853.17 Mn | 686.46 Mn |
| 7 | Jefferson Capital | 1.23 Bn | 1.21 Bn | - |
| 8 | Upbound | 1.11 Bn | 1.00 Bn | 594.84 Mn |
| 9 | Lufax Holding | 1.08 Bn | -1.19 Bn | - |
| 10 | Metalla Royalty & Streaming | 957.79 Mn | 946.72 Mn | 4.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -82.60% |
| Mar 31, 2026 | 31.56% |
| Dec 31, 2025 | -19.88% |
| Sep 30, 2025 | 379.53% |
| Jun 30, 2025 | -78.68% |
| Mar 31, 2025 | 29.93% |
| Dec 31, 2024 | -58.54% |
| Sep 30, 2024 | 314.84% |
| Jun 30, 2024 | 4,648.96% |
| Mar 31, 2024 | -100.60% |
| Dec 31, 2023 | 487.81% |
| Sep 30, 2023 | -65.25% |
| Jun 30, 2023 | -30.99% |
| Mar 31, 2023 | 183.45% |
| Dec 31, 2022 | -376.77% |
| Sep 30, 2022 | -55.16% |
| Jun 30, 2022 | 283.81% |
| Mar 31, 2022 | 138.64% |
| Dec 31, 2021 | -75.80% |
| Sep 30, 2021 | -72.51% |